Imatinib
Dermatofibrosarcoma
Novartis PharmaceuticalsSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Dermatofibrosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gdc-0449 National Cancer Institute (NCI) | Phase 1/2 | CCC |
rg4733 National Cancer Institute (NCI) | Phase 1/2 | CC |
Same molecule, other indications
Imatinib is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
71 / 100
View asset →B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
69 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →